ASPHF (Ascentage Pharma Group International) Growth Rank: 10 (As of Jul. 27, 2026) — 43% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASPHF Ascentage Pharma Group International ASPHF
66 GF Score
Price $4.53
GF Value $7.46
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International Growth Rank?

Ascentage Pharma Group International ASPHF 66 Growth Rank is 10 as of Jul. 27, 2026, which is 43% above its 10-year median of 7.00. GuruFocus rates ASPHF with a GF Score™ of 66/100 and a GF Value™ of $7.46 (Possible Value Trap). The stock has 7 warning signs investors should review.

Ascentage Pharma Group International has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Ascentage Pharma Group International Growth Rank Related Terms

ASPHF vs VRTX, REGN, RVMD: Growth Rank Comparison

For the Biotechnology subindustry, Ascentage Pharma Group International's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Growth Rank distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Growth Rank falls into.


ASPHF
66GF Score
Ascentage Pharma Group International ASPHF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Ascentage Pharma Group International (ASPHF) has a Growth Rank of 10 as of Jul. 27, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Ascentage Pharma Group International and its competitors. This is 43% above median its historical median of 7.00. Over the past decade, Ascentage Pharma Group International's Growth Rank has ranged from 4.00 to 10.00.
Is Ascentage Pharma Group International's Growth Rank too high?
Ascentage Pharma Group International's current Growth Rank of 10 is 43% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, Ascentage Pharma Group International has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Growth Rank compare to VRTX and REGN?
Ascentage Pharma Group International's Growth Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Ascentage Pharma Group International's own Growth Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Ascentage Pharma Group International and its competitors. Ascentage Pharma Group International's current Growth Rank is 10, which is 43% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $7.46, compared to a current price of $4.53 — trading 39.3% below its estimated fair value. The current Growth Rank is 10, which is 43% above median its 10-year median of 7.00. Ascentage Pharma Group International's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Growth Rank is 10 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 39.3% below its estimated GF Value™ of $7.46. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

  • Growth Rank: 10 (43% above median its 10-year median of 7.00)
  • GF Value™: $7.46 vs. price of $4.53 (39.3% below fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
66GF Score

Get the complete analysis for ASPHF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$7.46
GF Value